Preventive Vaccine Market to Reach $96.5 Billion by 2035

Global preventive vaccine Market is witnessing strong expansion, driven by increasing immunisation coverage, rising infectious disease burden, and accelerated government-led vaccination programs worldwide. The market was valued at $58.1 billion in 2025 and is projected to reach $96.5 billion by 2035, growing at a CAGR of 5.20% during the forecast period. According to the World Health Organisation (WHO), routine immunisation currently prevents 4–5 million deaths annually, highlighting the critical role of preventive vaccines in global public health systems. WHO also reports that global vaccine coverage for essential childhood vaccines (DTP3) remains above 80% globally, though regional disparities continue to drive new investments in vaccine access and cold-chain infrastructure. This expanding immunisation footprint is directly supporting sustained demand growth in the preventive vaccine industry.

Browse the full report description of “Preventive Vaccine Market Size, Share & Trends Analysis Report, By Vaccine Type – Live Attenuated Vaccines, Inactivated Vaccines, Subunit & Recombinant Vaccines, Toxoid Vaccines, mRNA Vaccines, Viral Vector Vaccines, By Disease Indication – Respiratory, Pediatric, Hepatitis, HPV, Meningococcal & Pneumococcal, Travel & Endemic Diseases, By Age Group, By Route of Administration, Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/preventive-vaccine-market

A major macro driver fueling the market is the increasing burden of infectious diseases and pandemic preparedness initiatives. WHO data indicates that influenza alone causes 290,000 to 650,000 respiratory deaths annually worldwide, while pneumococcal diseases remain a leading cause of child mortality in developing economies. These disease burdens are pushing governments to strengthen vaccination mandates, thereby accelerating demand for advanced vaccine platforms.

Among vaccine types, mRNA vaccines represent the fastest-growing segment due to their rapid development cycle, high efficacy, and scalability. This technology has gained strong adoption following COVID-19, with expanding applications in influenza, RSV, and oncology preventive indications. Governments and manufacturers are increasingly investing in mRNA platforms to enhance pandemic readiness and next-generation immunisation strategies. Key industry players are actively pursuing strategic initiatives to strengthen their market position, for instance,

• In September 2025, Pfizer, in collaboration with BioNTech, advanced its next-generation mRNA COVID-19 vaccine (2025–2026 formula) with strong clinical trial results demonstrating improved immune response against new variants such as LP.8.1. The companies also moved forward with regulatory submissions following FDA guidance for updated vaccine composition. This represents a product upgrade and lifecycle expansion strategy, where existing vaccines are reformulated to maintain efficacy, reinforcing recurring revenue streams in the preventive vaccine market.

Market Coverage

• The market number available for – 2025–2035
  • Base year- 2025
  • Forecast period- 2026–2035
  • Segment Covered-
  o By Vaccine Type
  o By Route of Administration
  o By Disease Indication
  o By Age Group

o Competitive Landscape – Pfizer, GlaxoSmithKline, Sanofi, Merck & Co., and Moderna

Key questions addressed by the report.

• What is the market growth rate?
  • Which segment and region dominate the market in the base year?
  • Which segment and region will project the fastest growth in the market?
  • Who is the leader in the market?
  • How are players addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Preventive Vaccine Market Report Segment

By Vaccine Type

• Live Attenuated Vaccines
  • Inactivated (Killed) Vaccines
  • Subunit, Recombinant & Conjugate Vaccines
  • Toxoid Vaccines
  • mRNA Vaccines
  • Viral Vector Vaccines

By Disease Indication

• Respiratory Diseases (Influenza, COVID-19, Pneumonia)
  • Pediatric Diseases (MMR, Polio, DTP)
  • Hepatitis (A, B)
  • HPV (Human Papillomavirus)
  • Meningococcal & Pneumococcal Diseases
  • Travel & Endemic Diseases (Yellow Fever, Typhoid, Rabies)

By Age Group

• Pediatric (0–17 years)
  • Adult (18–64 years)
  • Geriatric (65+ years)

By Route of Administration

• Injectable (Intramuscular / Subcutaneous)
  • Oral Vaccines
  • Nasal Vaccines

Global Preventive Vaccine Market Report Segment by Region

North America

• United States
  • Canada

Europe

• UK
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe

Asia-Pacific

• China
  • India
  • Japan
  • South Korea
  • Australia and New Zealand
  • ASEAN Economies
  • Rest of Asia-Pacific

Rest of the World

• Latin America
  • Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/preventive-vaccine-market